FDA 483 - Dr. J Skinclinic, Inc - March 23, 2026

Between March 18 and March 23, 2026, the U.S. Food and Drug Administration (FDA) conducted an inspection of Dr. J Skinclinic, Inc., a contract manufacturer located in Cerritos, California. The resulting Form 483 outlines several significant lapses in quality control and manufacturing standards under the regulatory framework of the Federal Food, Drug, and Cosmetic Act. Key violations identified include a failure to adequately test deionized water used for cleaning equipment, with the firm ignoring internal limits for bacterial contamination and chemical purity. Additionally, the company distributed bulk drug products without verifying the identity or strength of active ingredients and failed to perform required identity testing on raw materials. Investigators also noted a lack of cleaning validation for shared equipment, which poses a risk of cross-contamination, and an absence of validated manufacturing processes. Administrative deficiencies included the failure to conduct annual product quality reviews from 2022 to 2025, poor documentation practices, and inadequate training for senior management. Dr. J Skinclinic, Inc. is expected to review these observations and implement comprehensive corrective actions. The firm should submit a formal response to the FDA detailing their remediation plan to ensure future compliance with pharmaceutical manufacturing standards. These observations represent preliminary findings and are not a final determination of the company’s regulatory status.